Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

18 lutego 2020 zaktualizowane przez: Genentech, Inc.

A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease

This Phase II, open-label extension (OLE), multicenter study will evaluate the long-term safety and tolerability of crenezumab in participants with mild to moderate Alzheimer's disease who have participated in and completed the treatment period of the Phase II Study ABE4869g (NCT01343966) or ABE4955g (NCT01397578). Participants who received placebo in Study ABE4869g (NCT01343966) or ABE4955g (NCT01397578) will receive crenezumab. Anticipated time on study treatment is 144 weeks.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

360

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Francja
      • Bron, Francja, 69677
        • Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie
      • Limoges, Francja, 87042
        • CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique
      • Nancy, Francja, 54035
        • Hopital Central; Neurologie
      • Nantes, Francja, 44093
        • Hopital Nord Laennec
      • Rouen, Francja, 76031
        • CHU de Rouen Hopital; Service de Neurologie
      • Strasbourg, Francja, 67091
        • Hôpital Civil de Strasbourg
  • Hiszpania
      • Albacete, Hiszpania, 2006
        • Complejo Hospitalario Universitario de Albacete
      • Madrid, Hiszpania, 28006
        • Clinica Ruber, 4 planta; Servicio de Neurologia
    • Barcelona
      • BArcelon, Barcelona, Hiszpania, 08034
        • Fundacio ACE
      • San Cugat Del Valles, Barcelona, Hiszpania, 08195
        • Hospital General De Catalunya
    • Guipuzcoa
      • San Sebastian, Guipuzcoa, Hiszpania, 20009
        • Policlinica Guipuzcoa
    • Vizcaya
      • Barakaldo, Vizcaya, Hiszpania, 48903
        • Hospital de Cruces; Servicio de Neurologia
  • Kanada
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 3G8
        • The Med Arts Health Rsrch Grp
      • Vancouver, British Columbia, Kanada, V6T 2B5
        • University of British Columbia Hospital; Division of Neurology
    • Nova Scotia
      • Halilfax, Nova Scotia, Kanada, B3H 2E1
        • Capitol District Health Authority
    • Ontario
      • Burlington, Ontario, Kanada, L7M 4Y1
        • JBN Medical Diagnostic Services Inc.
      • Kingston, Ontario, Kanada, K7L 2V7
        • Hotel Dieu Hospital
      • London, Ontario, Kanada, N6C 5J1
        • St. Joseph's HC-Parkwood Hosp
      • Ottawa, Ontario, Kanada, K1N 5C8
        • Bruyere Continuing Care
      • Peterborough, Ontario, Kanada, K9H 2P4
        • Kawartha Centre - Redefining Healthy Aging
      • Toronto, Ontario, Kanada, M3B 2S7
        • Toronto Memory Program (Neurology Research Inc.)
    • Quebec
      • Greenfield Park, Quebec, Kanada, J4V 2J2
        • Clinique Neuro Rive-Sud
      • Montreal, Quebec, Kanada, H1T 2M4
        • Hôpital Maisonneuve-Rosemont/Polyclinique;Recherche Clinique
      • Quebec City, Quebec, Kanada, G1J 1Z4
        • CHAUQ Hopital Enfant-Jesus
      • Verdun, Quebec, Kanada, H4H 1R3
        • McGill Univeristy; Douglas Mental Health University Institute; Neurological and Psychiatric
  • Niemcy
      • Berlin, Niemcy, 12203
        • Univ Berlin; Klin fur Psychi & Psycho Charite
      • Günzburg, Niemcy, 89312
        • Bezirkskrankenhaus Günzburg
      • Mannheim, Niemcy, 68159
        • Zentralinstitut fuer Seelische Gesundheit
      • Munchen, Niemcy, 81377
        • Ludwig-Maximilians-Univ.
      • Munchen, Niemcy, 81675
        • Klinikum rechts der Isar der Technischen Universität München
      • Tubingen, Niemcy, 72076
        • Universitätsklinik Tübingen; Psychiatrie und Psychotherapie
  • Stany Zjednoczone
    • Arizona
      • Phoenix, Arizona, Stany Zjednoczone, 85006
        • Banner Alzheimer's Institute
      • Scottsdale, Arizona, Stany Zjednoczone, 85259
        • Mayo Clinic
      • Sun City, Arizona, Stany Zjednoczone, 85351
        • Banner Sun Health Research Insitute
    • California
      • Encino, California, Stany Zjednoczone, 91316
        • Pharmacology Research Inst
      • Fresno, California, Stany Zjednoczone, 93720
        • Margolin Brain Institute
      • La Jolla, California, Stany Zjednoczone, 92037
        • Univ of CA San Diego; Neurosciences Comp.Alzheimer's
      • Los Angeles, California, Stany Zjednoczone, 90095
        • University of California Los Angeles (UCLA)
      • Los Angeles, California, Stany Zjednoczone, 90033
        • USC School of Medicine
      • Newport Beach, California, Stany Zjednoczone, 92660
        • Pharmacology Research Inst
      • Oxnard, California, Stany Zjednoczone, 93030
        • Pacific Neuroscience Med Grp
      • Palo Alto, California, Stany Zjednoczone, 94304
        • Stanford Univ Medical Center
      • Sacramento, California, Stany Zjednoczone, 95817
        • University of California Davis Medical System
      • San Diego, California, Stany Zjednoczone, 92103
        • Pacific Research Network - PRN
      • San Francisco, California, Stany Zjednoczone, 94117
        • Uni of California San Francisco
      • Santa Rosa, California, Stany Zjednoczone, 95403
        • Redwood Regional Medical Group
    • Connecticut
      • New Haven, Connecticut, Stany Zjednoczone, 06511
        • Yale University
    • Florida
      • Boca Raton, Florida, Stany Zjednoczone, 33431
        • Florida Atlantic University; College of Medicine
      • Brooksville, Florida, Stany Zjednoczone, 34601
        • Meridien Research
      • Delray Beach, Florida, Stany Zjednoczone, 33445
        • Brain Matters Research, Inc.
      • Miami, Florida, Stany Zjednoczone, 33137
        • Miami Jewish Health Systems; Clinical Research
      • Naples, Florida, Stany Zjednoczone, 34105
        • Collier Neurologic Specialists
      • Orlando, Florida, Stany Zjednoczone, 32806
        • Bioclinica Research
      • Tampa, Florida, Stany Zjednoczone, 33609
        • Axiom Clinical Research of Florida
      • West Palm Beach, Florida, Stany Zjednoczone, 33407
        • Premiere Research Institute
    • Georgia
      • Decatur, Georgia, Stany Zjednoczone, 30033
        • DeKalb Neurology Associates
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60612
        • Rush Alzheimer's Disease Cntr.
      • Elk Grove Village, Illinois, Stany Zjednoczone, 60007
        • Alexian Brothers Neurosci Inst
    • Indiana
      • Indianapolis, Indiana, Stany Zjednoczone, 46202
        • Indiana Univ School of Med
    • Louisiana
      • New Orleans, Louisiana, Stany Zjednoczone, 70114
        • Louisiana Research Associates
    • Mississippi
      • Hattiesburg, Mississippi, Stany Zjednoczone, 39401
        • Hattiesburg Clinic
    • Missouri
      • Saint Louis, Missouri, Stany Zjednoczone, 63132
        • Millennium Psychiatric Associates, LLC
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89106
        • Cleveland Clinic Lou Ruvo; Center for Brain Research
    • New Jersey
      • Eatontown, New Jersey, Stany Zjednoczone, 07724
        • Memory Enhancement Center of America, Inc.
      • Mount Arlington, New Jersey, Stany Zjednoczone, 07856
        • NeuroCognitive Institute
    • New York
      • Latham, New York, Stany Zjednoczone, 12210
        • Empire Neurology, PC
      • Manhasset, New York, Stany Zjednoczone, 11030
        • Litwin Zucker Research Ctr.; Feinstein Inst. Med. Rsch.
      • New York, New York, Stany Zjednoczone, 10032
        • Columbia University Medical Center
      • Rochester, New York, Stany Zjednoczone, 14627
        • University of Rochester Medical Center; Monroe Community Hospital
      • Rochester, New York, Stany Zjednoczone, 14642
        • Investigational Drug Service; Univ of Rochester Medical Ctr
    • North Carolina
      • Raleigh, North Carolina, Stany Zjednoczone, 27607-6520
        • Raleigh Neurology Associates
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97210
        • Summit Research Network Inc.
    • Pennsylvania
      • Jenkintown, Pennsylvania, Stany Zjednoczone, 19046
        • The Clinical Trial Center, LLC
    • Rhode Island
      • East Providence, Rhode Island, Stany Zjednoczone, 02914
        • Rhode Island Mood & Memory Research Institute
      • Providence, Rhode Island, Stany Zjednoczone, 02906
        • Butler Hospital
    • South Carolina
      • North Charleston, South Carolina, Stany Zjednoczone, 29425
        • Medical Uni of South Carolina
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77030
        • Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine
    • Vermont
      • Bennington, Vermont, Stany Zjednoczone, 05201
        • Clinical Neuroscience Research Associates, Inc.
  • Zjednoczone Królestwo
      • Bath, Zjednoczone Królestwo, BA1 3NG
        • The Rice Centre; Royal United Hospital
      • Brentford, Zjednoczone Królestwo, TW8 8DS
        • West London Research Unit; Brentford Lodge
      • Brighton, Zjednoczone Królestwo, BN2 5BE
        • Royal Sussex County Hospital, CIRU Level 5
      • Glasgow, Zjednoczone Królestwo, G20 0XA
        • Glasgow Memory Clinic
      • London, GT LON, Zjednoczone Królestwo, WC1N 3BG
        • The National Hospital for Neurology & Neurosurgery; Dementia Research Center
      • Southampton, Zjednoczone Królestwo, SO30 3JB
        • Moorgreen Hospital; Memory Assessment & Rsch Ctr
      • Southampton, Zjednoczone Królestwo, SO16 6YD
        • Southampton General Hospital; Pharmacy
      • Swindon, Zjednoczone Królestwo, SN3 6BW
        • Great Western Hosp.; Kingshill Research Ctr

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

50 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Previous participation in Study ABE4869g or ABE4955g and completion of the Week 73 visit
  • Adequate visual and auditory acuity, in the investigator's judgment, to allow for neuropsychological testing
  • Availability of a person ("caregiver") who can provide information on activities of daily living and behavior in order to complete the study-specific assessments
  • Diagnosis of probable Alzheimer's disease according to the National Institute on Neurological and Communication Disease and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria (McKhann et al. 1984)
  • Mini-Mental State Examination (MMSE) score of 10 or more at screening (Folstein et al. 1975)
  • For male participants with partners with reproductive potential, agreement to use a reliable means of contraception (e.g., condoms) during the study and for at least 8 weeks following the last dose of study drug
  • For female participants, a negative pregnancy test at screening

Exclusion Criteria:

  • Early treatment and/or study discontinuation prior to completion of the Week 73 visit of Genentech Study ABE4869g or ABE4955g
  • Early discontinuation from the treatment schedule of a prior version of Study GN28525 for safety reasons. If treatment discontinuation occurred for safety reasons, participants may not re-start dosing on extended treatment schedules offered in amendments to Study GN28525
  • Inability to tolerate Magnetic Resonance Imaging (MRI) procedures or contraindication to MRI
  • Female participants with reproductive potential: Female participants must either have undergone documented surgical sterilization or have not experienced menstruation for at least 12 consecutive months
  • Severe or unstable medical condition that, in the opinion of the investigator or Sponsor, would interfere with the participant's ability to complete the study assessments or would require the equivalent of institutional or hospital care
  • History or presence of clinically evident vascular disease potentially affecting the brain
  • History of severe, clinically significant central nervous system trauma
  • History or presence of clinically relevant intracranial tumor
  • Presence of infections that affect the brain function or history of infections that resulted in neurologic sequelae
  • History or presence of systemic autoimmune disorders potentially causing progressive neurologic disease
  • History or presence of a neurologic disease other than Alzheimer's disease that may affect cognition
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
  • Evidence of malignancies (except squamous cell cancer or basal cell cancer of the skin), acute infections, renal failure that requires dialysis, or other unstable medical disease not related to Alzheimer's disease that, in the investigator's opinion, would preclude participant's participation. Cancer that is not being actively treated with anti-cancer therapy or radiotherapy as well as cancers which are considered to have low probability of recurrence are allowed
  • History or presence of atrial fibrillation that, in the investigator's judgment, poses a risk for future stroke
  • Chronic kidney disease of Stage greater than or equal to (>=) 4, according to the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines for chronic kidney disease (CKD)
  • Impaired hepatic function
  • Impaired coagulation (activated partial thromboplastin time [aPTT] greater than [>] 1.2 times upper limit of normal [ULN])
  • Platelet count less than (<) 100,000 per microliter (mcL)
  • Presence at screening of superficial siderosis of central nervous system, more than 8 cerebral microhemorrhages, or evidence of a prior cerebral macrohemorrhage
  • Presence at screening of any other significant cerebral abnormalities, including ARIA-E
  • Treatment with anticoagulation medications within 2 weeks prior to enrollment. Clopidogrel, dipyridamole, and aspirin are permitted
  • Treatment with anticholinergic antidepressants, typical antipsychotics, or barbiturates within 2 weeks prior to enrollment. All other antidepressants and atypical antipsychotics are allowed with certain restrictions as defined in the protocol
  • Chronic use of opiates, opioids, or benzodiazepines
  • Any biologic therapy within 75 weeks prior to enrollment
  • Any investigational agent (other than crenezumab) within 75 weeks prior to enrollment
  • Treatment with anticholinergic antidepressants, typical antipsychotics, barbiturates, or narcotics within 5 half-lives or 3 months prior to screening, whichever is longer. All other antidepressants and atypical antipsychotics are allowed. Chronic use of benzodiazepines is not allowed; however, the intermittent use of benzodiazepines is allowed, except within 2 days prior to any neurocognitive assessment

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Crenezumab
Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
Lek: Crenezumab
Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
Inne nazwy:
  • RO5490245

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With Adverse Events (AEs)
Ramy czasowe: Up to 50 months
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. . An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Up to 50 months
Percentage of Participants by Nature of AEs
Ramy czasowe: Up to 50 months
A serious adverse event (SAE) is any AE that meets any of the following criteria: fatal, life threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect in a neonate/infant. Non-SAE of special interest for this study include the following: cerebral vascular edema, Superficial siderosis of central nervous system, cerebral micro-hemorrhages or macro-hemorrhages, pneumonia, liver injury.
Up to 50 months
Percentage of Participants by Severity of AEs
Ramy czasowe: Up to 50 months
AE severity grading scale for the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0 was used for assessing adverse event severity. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on the following general guideline: Grade 1) mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated, Grade 2) moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL), Grade 3) severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL, Grade 4) life-threatening consequences; urgent intervention indicated, Grade 5) death related to AE.
Up to 50 months
Percentage of Participants With Human Anti-Therapeutic Antibody (ATA) Formation
Ramy czasowe: Pre-dose (Day-14), predose at Week 25, 49, 97, Follow-up Week 8 (Week 153) and 12 (Week 157)
ATA is a measurement to explore the potential relationship of immunogenicity response with pharmacokinetics, safety and efficacy. Percentage of participants at post-baseline with positive results for ATA against crenezumab are reported.
Pre-dose (Day-14), predose at Week 25, 49, 97, Follow-up Week 8 (Week 153) and 12 (Week 157)
Percentage of Participants With Amyloid-Related Imaging Abnormalities Edema/Effusions (ARIA-E)
Ramy czasowe: Baseline, Weeks 23, 47, 71, 97, 121 and 153
Alzheimer's disease (AD) is associated with ARIA. The occurrence of imaging abnormalities believed to represent cerebral vasogenic edema, has been reported in association with the investigational use of compounds that are intended to treat Alzheimer's disease by reducing Abeta in the brain. Here, the percentage of participants with symptomatic and asymptomatic ARIA-E were reported.
Baseline, Weeks 23, 47, 71, 97, 121 and 153
Percentage of Participants With Amyloid-Related Imaging Abnormalities-Hemorrhage (ARIA-H)
Ramy czasowe: Baseline, Weeks 23, 47, 71, 97, 121 and 153
AD is associated with ARIA. Cerebral micro-hemorrhages (microbleeds [MBs]) are radiologically defined as small dot-like foci of signal loss observed on magnetic resonance imaging (MRI) sequences sensitive for paramagnetic tissue properties. The occurrence of MBs has also been identified as an adverse event in anti-amyloid vaccination trials, and together with superficial siderosis, they have been termed ARIA-H.
Baseline, Weeks 23, 47, 71, 97, 121 and 153

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Genentech, Inc.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

7 grudnia 2012

Zakończenie podstawowe (Rzeczywisty)

8 lutego 2017

Ukończenie studiów (Rzeczywisty)

8 lutego 2017

Daty rejestracji na studia

Pierwszy przesłany

6 listopada 2012

Pierwszy przesłany, który spełnia kryteria kontroli jakości

6 listopada 2012

Pierwszy wysłany (Oszacować)

8 listopada 2012

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

20 lutego 2020

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

18 lutego 2020

Ostatnia weryfikacja

1 lutego 2020

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • GN28525
  • 2012-003242-33 (Numer EudraCT)

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj